

DAFTAR PUSTAKA

- Abancens M, Bustos V, Harvey H, McBryan J, Harvey BJ. Sexual Dimorphism in Colon Cancer. *Front Oncol*. 2020 Dec 9;10:607909. doi: 10.3389/fonc.2020.607909. PMID: 33363037; PMCID: PMC7759153.
- Abbas, A. K., Lichtman, A. H. and Pillai, S. (eds) (2018b) 'Immunity to Tumors', in *Cellular and Molecular Immunology*. 9th edn. Philadelphia: Elsevier, pp. 397–416
- Abedalthagafi, M. (2018). *Oncotarget-09-35458*. 9(83), 35458–35469. <https://pubmed.ncbi.nlm.nih.gov/30459937/>.
- Abraham L. Kierszenbaum, Laura L..2016. Histology and cell biology Fourth edition. Library of Congress Cataloging-in-Publication Data Kierszenbaum
- Ahmed, M. (2020). Colon Cancer: A Clinician's Perspective in 2019. *Gastroenterology Research*, 13(1), 1–10. <https://doi.org/10.14740/gr1239>
- Aktekin, A., Özkara, S., Gürleyik, G., Odabaşı, M., Müftüoğlu, T., & Sağlam, A. (2015). The Factors Effecting Lymphovascular Invasion in Adenocarcinoma of the Colon and Rectum. *Indian Journal of Surgery*, 77(December), 314–318. <https://doi.org/10.1007/s12262-013-0816-5>
- Alexander, J. L., Wilson, I. D., Teare, J., et al. (2019). Gut microbiota modulation of chemotherapy efficacy and toxicity. *Nature Reviews Gastroenterology & Hepatology*, 16(6), 356-372.
- Antohe, M., Nedelcu, R. I., Nichita, L., Popp, C. G., Cioplea, M., Brinzea, A., ... Bleotu, C. (2019). Tumor infiltrating lymphocytes : The regulator of melanoma evolution (Review), 4155–4161. <https://doi.org/10.3892/ol.2019.9940>
- Arikunto, S. (2016). *Prosedur Penelitian Suatu Praktek*. Jakarta: Rineka Cipta. Austin
- JW, Lu P, Majumder P, Ahmed R, Boss JM. STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. *J Immunol*. 2014; 192:4876– 4886. [PubMed: 24711622]
- Baer, C., Claus, R., & Plass, C. (2013). Genome-wide epigenetic regulation of miRNAs in cancer. *Cancer Research*, 73(2), 473–477. <https://doi.org/10.1158/0008-5472.CAN-12-3731>
- Bader, J. E., Voss, K., & Rathmell, J. C. (2020). Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. *Molecular Cell*, 78(6), 1019-1033
- Bai Z, Zhou Y, Ye Z, Xiong J, Lan H, Wang F. Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. *Front Immunol*. 2022 Jan 14;12:808964. doi: 10.3389/fimmu.2021.808964. PMID: 35095898; PMCID: PMC8795622.
- Baisheng Lin, Likun Du, Hongmei Li, Xiao Zhu, Liao Cui, Xiaosong Li, Tumor- infiltrating lymphocytes: Warriors fight against tumors powerfully, *Biomedicine & Pharmacotherapy*, Volume 132,2020,110873,ISSN 0753-

3322,<https://doi.org/10.1016/j.biopha.2020.110873>.
(<https://www.sciencedirect.com/science/article/pii/S0753332220310659>)

Bally AP, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, Boss JM. NF-kappaB Regulates PD-1 Expression in Macrophages. *J Immunol*. 2015; 194:4545– 4554. [PubMed: 25810391]

Bally AP, Austin JW, Boss JM. Genetic and Epigenetic Regulation of PD-1 Expression. *J Immunol*. 2016 Mar 15;196(6):2431-7. doi: 10.4049/jimmunol.1502643. PMID: 26945088; PMCID: PMC4780223.

Bateman, A. C. (2020). DNA mismatch repair proteins: Scientific update and practical guide. *Journal of Clinical Pathology*, 74(4), 264–268. <https://doi.org/10.1136/jclinpath-2020-207281>.

Battle, E., & Massagué, J. (2019). Transforming growth factor- β signaling in immunity and cancer. *Immunity*, 50(4), 924-940.

Bedard, P. L., Hansen, A. R., Ratain, M. J., & Siu, L. L. (2013). Tumour heterogeneity in the clinic. *Nature*, 501(7467), 355-364.

Bengsch, B., Ohtani, T., Khan, O., et al. (2018). Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. *Immunity*, 48(5), 1029-1045.

Betty R.K., Jonathan A.C.S. *Essential Medical Statistics*, 2th Ed. 2003. Blackwell Publishing. London ; 413 -419 p

Binnewies, M., Roberts, E. W., Kersten, K., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nature Medicine*, 24(5), 541-550

Blank, C. U., Haining, W. N., Held, W., et al. (2019). Defining 'T cell exhaustion'. *Nature Reviews Immunology*, 19(11), 665-674.

Bresalier, R.S, Kopetz S., & Brenner D.E. (2015). Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test? *Dig Dis Sci*;60(3):664-71. doi: 10.1007/s10620-015-3575-2. Epub 2015 Feb 14. PMID: 25680874.

Chamoto, K., Chowdhury, P. S., Kumar, A., & Honjo, T. (2020). Pathways for exhaustion and the development of PD-1 blockade therapy. *Nature*, 575(7782), 284-292

Chen, L., & Han, X. (2015). Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. *The Journal of Clinical Investigation*, 125(9), 3384- 3391.

Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z and Hu Y (2021) Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta- Analysis. *Front. Oncol*. 11:562315. doi: 10.3389/fonc.2021.562315

Chi, Z., Lu, Y., Yang, Y. et al. Transcriptional and epigenetic regulation of PD-1 expression. *Cell. Mol. Life Sci.* 78, 3239–3246 (2021). <https://doi.org/10.1007/s00018-020-03737-y>

Costa PA, Leoratti FM, Figueiredo MM, Tada MS, Pereira DB, Junqueira C, Soares IS, Barber DL, Gazzinelli RT, Antonelli LR. Induction of Inhibitory Receptors on T Cells During *Plasmodium vivax* Malaria Impairs Cytokine Production. *J Infect Dis*. 2015

- Cui G. The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. *Front Oncol.* 2021 Mar 5;11:573547. doi: 10.3389/fonc.2021.573547. PMID: 33763344; PMCID: PMC7982849.
- Dhand, N. K., & Khatkar, M. S. (2014). Statulator: An online statistical calculator. Sample Size Calculator for Comparing Two Independent Proportions. Accessed 3 September 2024 at <http://statulator.com/SampleSize/ss2P.html>
- Dejea, C. M., Wick, E. C., Hechenbleikner, E. M., et al. (2014). Microbiota organization is a distinct feature of proximal colorectal cancers. *Proceedings of the National Academy of Sciences*, 111(51), 18321-18326.
- Donini C, Galvagno F, Rotolo R, Massa A, Merlini A, Scagliotti GV, Novello S, Bironzo P, Leuci V, Sangiolo D. PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. *Br J Cancer.* 2023 Oct;129(9):1409-1416. doi: 10.1038/s41416-023-02363-2. Epub 2023 Jul 20. PMID: 37474722; PMCID: PMC10628145.
- Downs-Kelly E., Rubin B.P., & Goldblum, J.R. (2015). *Epithelial Neoplasms of the Large Intestine. In: Odze RD, Goldblum JR, ed. Odze and Goldblum Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas.* Philadelphia: Elsevier Saunder; 822–829 p.
- Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. *Cancer Res.* 2013; 73:3591–3603. [PubMed: 23633484]
- Durko, L., & Malecka-Panas, E. (2014). Lifestyle modifications and colorectal cancer. *Current Colorectal Cancer Reports*, 10(1), 45–54. <https://doi.org/10.1007/s11888-013-0203-4>.
- Fleming, M., Ravula, S., Tatishchev, S. F., & Wang, H. L. (2012). Colorectal carcinoma: Pathologic aspects. *Journal of Gastrointestinal Oncology*, 3(3), 153–173. <https://doi.org/10.3978/j.issn.2078-6891.2012.030>
- Fridman, W. H., Pages, F., Sautes-Fridman, C., & Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. *Nature Reviews Cancer*, 12(4), 298-306
- Fuchs, Talia L. MD*,†,‡; Sioson, Loretta BSc*; Sheen, Amy BSc*; Jafari-Nejad, Kambin MD, FRCPA§; Renaud, Christopher J. MBBS*,†; Andrici, Juliana MBBS, PhD||; Ahadi, Mahsa MD, FRCPA*,†,‡; Chou, Angela PhD, FRCPA*,†,‡; Gill, Anthony J. MD, FRCPA*,†,‡. Assessment of Tumor-infiltrating Lymphocytes Using International TILs Working Group (ITWG) System Is a Strong Predictor of Overall Survival in Colorectal Carcinoma: A Study of 1034 Patients. *The American Journal of Surgical Pathology* 44(4):p 536-544, April 2020. | DOI: 10.1097/PAS.0000000000001409
- Gajewski, T. F., Schreiber, H., & Fu, Y. X. (2013). Innate and adaptive immune cells in the tumor microenvironment. *Nature Immunology*, 14(10), 1014- 1022.
- Georgiou, A., Beers, S. A., & Cope, A. P. (2020). Harnessing the immune system to treat cancer. *British Journal of Cancer*, 123(2), 168-178

- Giovannucci E. Molecular Biologic and Epidemiologic Insights for Preventability of Colorectal Cancer. *J Natl Cancer Inst.* 2022 May 9;114(5):645-650. doi: 10.1093/jnci/djab229. PMID: 34978574; PMCID: PMC9086743.
- Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, Fulton A, Tamada K, Strome SE, Antony PA. Restoring immune function of tumor- specific CD4+ T cells during recurrence of melanoma. *J Immunol.* 2013; 190:4899–4909. [PubMed: 23536636]
- Guan, H., Wan, Y., Lan, J. et al. PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. *Sci Rep* 6, 35651 (2016). <https://doi.org/10.1038/srep35651>
- Gu, X., Dong, M., Liu, Z. et al. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. *Cancer Cell Int* 19, 146 (2019). <https://doi.org/10.1186/s12935-019-0861-7>
- Guo, L., Lin, Y. and Kwok, H. F. (2017) 'The Function and Regulation of PD-L1 in Immunotherapy', *ADMET & DMPK*, 5(3), pp. 159–172. doi: 10.5599/admet.5.3.442.
- Gubin MM, Vesely MD. Cancer Immunoediting in the Era of Immuno-oncology. *Clin Cancer Res.* 2022 Sep 15;28(18):3917-3928. doi: 10.1158/1078- 0432.CCR-21-1804. PMID: 35594163; PMCID: PMC9481657.
- Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, EllassaissSchaap J, Algazi A, Mateus C, Boasberg P, Tumei PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med.* 2013; 369:134–144. [PubMed: 23724846]
- Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. *Am J Cancer Res.* 2020 Mar 1;10(3):727-742. PMID: 32266087; PMCID: PMC7136921.
- Helmink, B. A., Reddy, S. M., Gao, J., & Zhang, S. (2020). B cells and tertiary lymphoid structures promote immunotherapy response. *Nature*, 577(7791), 549-555.
- Honda T, Egen JG, Lammermann T, Kastentmuller W, Torabi-Parizi P, Germain RN. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. *Immunity.* 2014; 40:235–247. [PubMed: 24440150]
- Hyuk, L. J. (2012). Prognostic Significance of Tumor-Infiltrating Lymphocytes for Patients With Colorectal Cancer. *Archives of Surgery*, 147(4), 366. <https://doi.org/10.1001/archsurg.2012.35>
- International Agency for Research on Cancer WHO. (2020). Cancer today. IARC Web site. <https://gco.iarc.fr/today/>.
- Iseki Y, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K, Ohira M. A new method for evaluating tumor- infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. *PLoS One.* 2018 Apr 26;13(4):e0192744. doi: 10.1371/journal.pone.0192744. PMID: 29698402; PMCID: PMC5919485.
- Ito, T., & Koyasu, S. (2014). Regulation of PD-1 expression and function. *Cancer Science*, 105(11), 1933-1941.

- Jakubowska, K., Kisielewski, W., Kańczuga-Koda, L., Koda, M., & Famulski, W. (2017). Stromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma. *Oncology Letters*, 14(6), 6421– 6432. <https://doi.org/10.3892/ol.2017.7013>
- Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018). Mechanisms of resistance to immune checkpoint inhibitors. *British Journal of Cancer*, 118(1), 9-16.
- Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. *Hum Vaccin Immunother*. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19. PMID: 30888929; PMCID: PMC6605868.
- Ju, X. *et al.* (2020) 'Regulation of PD-L1 Expression in Cancer and Clinical Implications in Immunotherapy', *American Journal of Cancer Research*, 10(1), pp. 1–11.
- Keum, N., Giovannucci, E. (2019). Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nat Rev Gastroenterol Hepatol*;16(12):713-732. doi: 10.1038/s41575-019-0189-8. Epub 2019 Aug 27. PMID: 31455888.
- Kim, M.K., Jo, S.I., Kim, SY. *et al.* PD-1-positive cells contribute to the diagnosis of inflammatory bowel disease and can aid in predicting response to vedolizumab. *Sci Rep* 13, 21329 (2023). <https://doi.org/10.1038/s41598-023-48651-y>
- Krzysztof M. Zak, Przemysław Grudnik, Katarzyna Magiera, Alexander Dömling, Grzegorz Dubin, Tad A. Holak, Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2, Structure, Volume 25, Issue 8, 2017, Pages 1163-1174, ISSN 0969-2126, <https://doi.org/10.1016/j.str.2017.06.011>. (<https://www.sciencedirect.com/science/article/pii/S0969212617301910>)
- Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. *J Clin Pathol*. 2018 Mar;71(3):189-194. doi: 10.1136/jclinpath-2017-204853. Epub 2017 Nov 2. PMID: 29097600.
- Lei, X., Lei, Y., Li, J. K., *et al.* (2020). Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. *Cancer Letters*, 470, 126-133.
- Lewis AL, Chaff J, Girotra M, Fischer GW. Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. *Br J Anaesth*. 2020 Mar;124(3):251-260. doi: 10.1016/j.bja.2019.11.034. Epub 2020 Jan 29. PMID: 32007241; PMCID: PMC7890563.
- Lee LH, Cavalcanti MS, Segal NH, Hechtman JF, Weiser MR, Smith JJ, Garcia- Aguilar J, Sadot E, Ntiamoah P, Markowitz AJ, Shike M, Stadler ZK, Vakiani E, Klimstra DS, Shia J. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. *Mod Pathol*. 2016 Nov;29(11):1433-1442. doi: 10.1038/modpathol.2016.139. Epub 2016 Jul 22. PMID: 27443512; PMCID: PMC5083129
- Lim, B., & Trinh, A. (2019). Spatial heterogeneity in the tumor microenvironment. *Nature Reviews Cancer*, 19(8), 494-507.
- Li, H., Wang, H., & Xia, Y. (2020). Regulation of PD-1 expression in cancer immunotherapy. *Frontiers in Immunology*, 11, 589192.
- Lin B, Du L, Li H, Zhu X, Cui L, Li X. Tumor-infiltrating lymphocytes: Warriors fight against

- tumors powerfully. *Biomed Pharmacother.* 2020 Dec;132:110873. doi: 10.1016/j.biopha.2020.110873. Epub 2020 Oct 14. PMID: 33068926.
- Lotfollahzadeh, S., Recio-Boiles, A., & Cagir, B. (2022). Colon Cancer. *StatPearls.* 2022 <https://www.ncbi.nlm.nih.gov/books/NBK470380>.
- Lugli, A., Kirsch, R., Ajioka, Y. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. *Mod Pathol* 30, 1299–1311 (2017). <https://doi.org/10.1038/modpathol.2017.46>
- Lu P, Youngblood BA, Austin JW, Rasheed Mohammed AU, Butler R, Ahmed R, Boss JM. Blimp-1 represses CD8 T cell expression of PD-1 using a feed- forward transcriptional circuit during acute viral infection. *J Exp Med.* 2014; 211:515–527. [PubMed: 24590765]
- Ma, J. W., Lai, T. J., Hu, S. Y., Lin, T. C., Ho, W. C., & Tsan, Y. T. (2020). Effect of ambient air pollution on the incidence of colorectal cancer among a diabetic population: A nationwide nested case-control study in Taiwan. *BMJ Open*, 10(10), 1–10. <https://doi.org/10.1136/bmjopen-2020-036955>
- Makaremi S, Asadzadeh Z, Hemmat N, Baghbanzadeh A, Sgambato A, Ghorbaninezhad F, Safarpour H, Argentiero A, Brunetti O, Bernardini R, Silvestris N, Baradaran B. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. *Biomedicines.* 2021 Aug 24;9(9):1075. doi: 10.3390/biomedicines9091075. PMID: 34572263; PMCID: PMC8467932.
- Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems. *J Pers Med.* 2022 Jun 29;12(7):1073. doi: 10.3390/jpm12071073. PMID: 35887569; PMCID: PMC9321150.
- Mathieu M, Cotta-Grand N, Daudelin JF, Thebault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. *Immunol Cell Biol.* 2013; 91:82–88. [PubMed: 23070399]
- McGranahan, N., & Swanton, C. (2017). Clonal heterogeneity and tumor evolution: past, present, and the future. *Cell*, 168(4), 613-628.
- McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019). CD8 T cell exhaustion during chronic viral infection and cancer. *Annual Review of Immunology*, 37, 457-495.
- McPherson RC, Konkel JE, Prendergast CT, Thomson JP, Ottaviano R, Leech MD, Kay O, Zandee SE, Sweenie CH, Wraith DC, Meehan RR, Drake AJ, Anderton SM. Epigenetic modification of the PD-1 (Pdc1) promoter in effector CD4(+) T cells tolerized by peptide immunotherapy. *eLife.* 2015:4.
- Moris, D., Ronnekleiv-Kelly, S., & Michalopoulos, N. (2021). The role of tumor microenvironment in colorectal cancer liver metastasis: implications for treatment. *Frontiers in Oncology*, 11, 548097.
- Murdani, A. (2013). *Tumor Kolorektal dalam Buku Ajar Ilmu Penyakit Dalam.* Jakarta: FKUI.
- Nagtegaal, I. D., Odze, R. D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K. M., Carneiro, F., & Cree, I. A. (2020). The 2019 WHO classification

- of tumours of the digestive system. *Histopathology*, 76(2), 182–188.
<https://doi.org/10.1111/his.13975>
- Nguyen, K. H., & Topalian, S. L. (2019). PD-1 and PD-L1 in cancer immunotherapy. *Nature Reviews Immunology*, 19(4), 247-262.
- Nikolaos Patsoukis *et al.*, Revisiting the PD-1 pathway. *Sci. Adv.* **6**, eabd2712 (2020).
 DOI: [10.1126/sciadv.abd2712](https://doi.org/10.1126/sciadv.abd2712)
- Noh, B.J., Kwak, J.Y. & Eom, DW. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. *BMC Cancer* 20, 58 (2020).
<https://doi.org/10.1186/s12885-020-6553-9>
- Notoadmojo, S. (2015). *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta.
- Ntomi V, Foukas P, Papaconstantinou D, Antonopoulou I, Pikoulis A, Panagiotides I, Pikoulis E, Syrigos K. **The clinical significance of PD-L1 in colorectal cancer**, Published online on: April 7, 2021, <https://doi.org/10.3892/or.2021.8043>
- Qi, C., Li, Y., Zeng, H. et al. Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer. *Clin Exp Med* 24, 162 (2024).
<https://doi.org/10.1007/s10238-024-01404-1>
- Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. *Cell Mol Immunol.* 2021 Apr;18(4):842-859. doi: 10.1038/s41423-020-00565-9. Epub 2020 Nov 2. PMID: 33139907; PMCID: PMC8115290.
- Passardi A, Canale M, Valgiusti M, Ulivi P. Immune Checkpoints as a Target for Colorectal Cancer Treatment. *Int J Mol Sci.* 2017 Jun 21;18(6):1324. doi: 10.3390/ijms18061324. PMID: 28635639; PMCID: PMC5486145.
- Pauken, K. E., & Wherry, E. J. (2015). Overcoming T cell exhaustion in infection and cancer. *Trends in Immunology*, 36(4), 265-276.
- Philip, M., & Schietinger, A. (2018). CD8+ T cell differentiation and dysfunction in cancer. *Nature Reviews Immunology*, 18(11), 747-762
- Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr, Taylor C, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. *Appl Immunohistochem Mol Morphol.* 2015 Sep;23(8):541-9. doi: 10.1097/PAI.0000000000000256. PMID: 26317305; PMCID: PMC4561627
- Patel, S., & Sharma, P. (2021). Regulation of PD-1 expression in cancer: A molecular perspective. *Cancers*, 13(21), 6194.
- Putranto, A.S. (2022). Manajemen Kanker Kolorektal. *Medicinus*, 35(3), 3–10.
<https://doi.org/10.56951/medicinus.v35i3.99>
- Pranata, A. A. N. S., Dewi, N. N. A., & Sumadi, I. W. J. (2021). Karakteristik Pasien Kanker Kolorektal di Rumah Sakit Umum Pusat Sanglah Tahun 2017. *Jurnal Medika Udayana*, 10(3), 53–57.
- Ranganathan, R., & Chen, J. (2022). Regulation of PD-1 expression in cancer: A therapeutic target. *Nature Reviews Cancer*, 22(3), 197-212.

- Rawla, P., Sunkara, T., & Barsouk, A. (2019). Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. *Przegląd Gastroenterologiczny*, 14(2), 89–103.
<https://doi.org/10.5114/pg.2018.81072>
- Rebecca L. Siegel MPH, Nikita Sandeep Wagle MBBS, MHA, PhD, Andrea Cercek MD, Robert A. Smith PhD, Ahmedin Jemal DVM, PhD. Colorectal cancer statistics, 2023. CA: A Cancer Journal for Clinicians, <https://doi.org/10.3322/caac.21772>
- Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. *Science*, 359(6382), 1350-1355.
- Rimm, D. L., Han, G., Taube, J. M., et al. (2017). A prospective, multi- institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. *JAMA Oncology*, 3(8), 1051-1058.
- Rosenbaum, M. W., Bledsoe, J. R., Morales-Oyarvide, V., Huynh, T. G., & Mino-Kenudson, M. (2016). PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. *Modern Pathology*, 29(9), 1104– 1112.
<https://doi.org/10.1038/modpathol.2016.95>
- Sanmamed, M. F., & Chen, L. (2018). A paradigm shift in cancer immunotherapy: from enhancement to normalization. *Cell*, 175(2), 313-326.
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., ... Loi, S. (2015). The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILS Working Group 2014. *Annals of Oncology*, 26(2), 259–271.
<https://doi.org/10.1093/annonc/mdu450>
- Saputra, E., Rahaju, A. S., & Ridholia, R. (2022). correlation of the expression of PD-L1 and Cyclin and Histopathological Grading in Colorectal Adenocarcinoma. *International Journal of Health Sciences*, 6(March), 1257–1268.
<https://doi.org/10.53730/ijhs.v6ns6.10630>
- Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers (Basel)*. 2021 Apr 22;13(9):2025. doi: 10.3390/cancers13092025. PMID: 33922197; PMCID: PMC8122718.
- Sears, C. L., & Garrett, W. S. (2014). Microbes, microbiota, and colon cancer. *Cell Host & Microbe*, 15(3), 317-328.
- Shan T, Chen S, Wu T, Yang Y, Li S, Chen X. PD-L1 expression in colon cancer and its relationship with clinical prognosis. *Int J Clin Exp Pathol*. 2019 May 1;12(5):1764-1769. Erratum in: *Int J Clin Exp Pathol*. 2022 Mar 15;15(3):155-156. PMID: 31933995; PMCID: PMC6947132.
- Shek D, Akhuba L, Carlino MS, Nagrial A, Moujaber T, Read SA, Gao B, Ahlenstiel G. Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. *Cancers (Basel)*. 2021 Aug 27;13(17):4345. doi: 10.3390/cancers13174345. PMID: 34503155; PMCID: PMC8430485.
- Sugiyono. (2017). *Metode Penelitian Bisnis*. Bandung: Alfabeta.

- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, Ji J. Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. *Biomark Res.* 2020 Aug 26;8:35. doi: 10.1186/s40364-020-00212-5. PMID: 32864132; PMCID: PMC7450549.
- Staron MM, Gray SM, Marshall HD, Parish IA, Chen JH, Perry CJ, Cui G, Li MO, Kaech SM. The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. *Immunity*. 2014; 41:802–814. [PubMed: 25464856]
- Swanson, B.J., Owens, S.R., & Frankel, W.L. (2016). *Neoplasms of the Colon*. In: *Lamps LW, Bellizzi AM, Frankel WL, Owens SR, Yantiss RK, ed. Neoplastic Gastrointestinal Pathology An Illustrated Guide*. New York: Demosmedical; 283–301 p.
- Sriwidayani, N. P. (2013). Mutasi K Ras pada Karsinogenesis Kanker Kolorektal. *Medicina*, 44(2), 97–100. <https://ojs.unud.ac.id/index.php/medicina/article/view/10055>.
- Taieb J, André T, Auclin E. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. *Cancer Treat Rev.* 2019 May;75:1-11. doi: 10.1016/j.ctrv.2019.02.002. Epub 2019 Feb 26. PMID: 30849607.
- The Human Protein Atlas project is funded by the Knut & Alice Wallenberg foundation. <https://www.proteinatlas.org/>
- Tilg, H., Adolph, T. E., Gerner, R. R., & Moschen, A. R. (2018). The intestinal microbiota in colorectal cancer. *Cancer Cell*, 33(6), 954-964.
- Thommen, D. S., & Schumacher, T. N. (2018). T cell dysfunction in cancer. *Cancer Cell*, 33(4), 547-562
- Togashi, Y., Shitara, K., & Nishikawa, H. (2019). Regulatory T cells in cancer immunosuppression—implications for anticancer therapy. *Nature Reviews Clinical Oncology*, 16(6), 356-371
- Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, Kollia GD, Gupta A, Pardoll DM, Sosman JA, Hodi FS. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2014; 32:1020–1030. [PubMed: 24590637]
- Turner, J.R. (2021). *The Gastrointestinal Tract. Dalam: Kumar V, Abbas AK, Pathology Basis of Disease*. Philadelphia: Saunders and Elsevier; h. 543-90.
- Triantafillidis, J. K., Vagianos, C., & Malgarinos, G. (2015). Colonoscopy in Colorectal Cancer Screening: Current Aspects. *Indian Journal of Surgical Oncology*, 6(3), 237–250. <https://doi.org/10.1007/s13193-015-0410-3>
- Valentini, A. M., Pinto, F. Di, Cariola, F., Guerra, V., Caruso, M. L., & Pirrelli,

- M. (2018). PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments, 9(9), 8584–8596.
- Van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020). CD8+ T cell states in human cancer: insights from single-cell analysis. *Nature Reviews Cancer*, 20(4), 218-232.
- Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021). Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. *Nature Reviews Immunology*, 21(8), 485-498.
- Volaric, Ashley MD*; Bacchi, Carlos E. MD, PhD†; Gru, Alejandro A. MD*. PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies. *The American Journal of Surgical Pathology* 44(10):p 1353-1366, October 2020. | DOI: 10.1097/PAS.0000000000001524
- Vranic S, Gatalica Z. PD-L1 testing by immunohistochemistry in immuno- oncology. *Biomol Biomed*. 2023 Feb 1;23(1):15-25. doi: 10.17305/bjbms.2022.7953. PMID: 35964287; PMCID: PMC9901897.
- Wang, L., Ren, F., Wang, Q., Baldridge, L. A., Monn, M. F., Fisher, K. W., ... Cheng, L. (2016). Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. *Molecular Diagnosis & Therapy*, 20(2), 175–181. <https://doi.org/10.1007/s40291-016-0188-1>
- Wang, X., Luo, Y., Huang, J., & Wei, J. (2021). Lymphovascular invasion as a prognostic factor in colorectal cancer: a systematic review and meta- analysis. *World Journal of Surgical Oncology*, 19(1), 47
- Wang HB, Yao H, Li CS, Liang LX, Zhang Y, Chen YX, Fang JY, Xu J. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy. *J Dig Dis*. 2017 Oct;18(10):574-581. doi: 10.1111/1751- 2980.12538. PMID: 28851046.
- Wang, X., & Ji, X. (2020). Sample size estimation in clinical research: from randomized controlled trials to observational studies. *Chest*, 158(1), S12- S20.
- Wei, C., & Zhu, X. (2019). Anti-IL-10R1 monoclonal antibody enhances T-cell- mediated immune response by blocking IL-10 autocrine loop. *Cell Research*, 29(3), 243-255.
- Wei Li, Fenglei Wu, Shaolin Zhao, Peiqin Shi, Shengjun Wang, Dawei Cui,Correlation between PD-1/PD-L1 expression and polarization in tumor- associated macrophages: A key player in tumor immunotherapy,Cytokine & Growth Factor Reviews,Volume 67,2022,Pages 49-57,ISSN 13596101,<https://doi.org/10.1016/j.cytogfr.2022.07.004>.(<https://www.sciencedirect.com/science/article/pii/S1359610122000545>)
- West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ahmed R. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. *J Clin Invest*. 2013; 123:2604–2615. [PubMed: 23676462]
- Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. *Nature Reviews Immunology*, 15(8), 486-499.
- Wong, M.C.S, Ding, H., Wang, J., SF Chan, P., & Huang, J. (2019). Prevalence and risk

- factors of colorectal cancer in Asia. *Intestinal Research*, 17(3), 317–329. <https://doi.org/10.5217/ir.2019.00021>
- Woo, S. R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y., ... & Gajewski, T. F. (2014). STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. *Immunity*, 41(5), 830-842. DOI: 10.1016/j.immuni.2014.10.017
- Wyk, H.C., Van, Roxburgh, C.S., Horgan, P.G., Foulis, A.F., & Mcmillan, D.C. (2014). The detection and role of lymphatic and blood vessel invasion in predicting survival in patients with node negative operable primary colorectal cancer. *Crit Rev Oncol / Hematol*, 90(1):77.
- Xi, Y., & Xu, P. (2021). Global colorectal cancer burden in 2020 and projections to 2040. *Translational Oncology*, 14(10), 101174. <https://doi.org/10.1016/j.tranon.2021.101174>
- Yayasan Kanker Indonesia. (2017). *Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia. Kanker di Indonesia tahun 2014, Data Histopatologik*. Jakarta: Yayasan Kanker Indonesia.
- Yang, L., Liu, S., He, W. *et al*. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. *BMC Cancer* 23, 221 (2023). <https://doi.org/10.1186/s12885-023-10610-1>
- Ye J, Ji X, Dennis PA, Abdullah H, Mukhopadhyay P. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta- Analysis. *Clin Pharmacol Ther*. 2020 Dec;108(6):1274-1288. doi: 10.1002/cpt.1956. Epub 2020 Jul 18. PMID: 32564368; PMCID: PMC7689755.
- Youngblood B, Noto A, Porichis F, Akondy RS, Ndhlovu ZM, Austin JW, Bordi R, Procopio FA, Miura T, Allen TM, Sidney J, Sette A, Walker BD, Ahmed R, Boss JM, Sekaly RP, Kaufmann DE. Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus- specific CD8 T cells. *J Immunol*. 2013; 191:540–544. [PubMed: 23772031]
- Zengde Chi;Yan Lu;Yinlong Yang;Bingqing Li;Peiyuan Lu; (2021). Transcriptional and epigenetic regulation of PD-1 expression . *Cellular and Molecular Life Sciences*, (), -. doi:10.1007/s00018-020-03737-y
- Zerdes, I., Matikas, A., Bergh, J. *et al*. Genetic, transcriptional and post- translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. *Oncogene* 37, 4639–4661 (2018). <https://doi.org/10.1038/s41388-018-0303-3>
- Zhang L, Chen Y, Wang H, Xu Z, Wang Y, Li S, Liu J, Chen Y, Luo H, Wu L, Yang Y, Zhang H, Peng H. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. *J Immunother Cancer*. 2021 Jun;9(6):e002356. doi: 10.1136/jitc-2021-002356. PMID: 34140315; PMCID: PMC8212410.
- Zhang, N., Yang, X., Piao, M. *et al*. Biomarkers and prognostic factors of PD- 1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. *Biomark Res* 12, 26 (2024). <https://doi.org/10.1186/s40364-023- 00535-z>
<https://www.neuromics.com/itrium/reference/D8xcc91x8x1/Datasheet.pdf>

LAMPIRAN

 KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431 			
REKOMENDASI PERSETUJUAN ETIK Nomor : 434/UN4.6.4.5.31/ PP36/ 2024			
Tanggal: 12 Juni 2024			
Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :			
No Protokol	UH24050376	No Sponsor	
Peneliti Utama	dr. Nur Rahmah Rasyid	Sponsor	
Judul Peneliti	HUBUNGAN EKSPRESI PROGRAMMED DEATH-1 (PD-1) DAN PROGRAMMED DEATH-LIGAND 1 (PDL-1) DENGAN GRADING TUMOR INFILTRATING LYMPHOCYTES (TILS) PADA ADENOKARSINOMA KOLOREKTAL		
No Versi Protokol	1	Tanggal Versi	29 Mei 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Universitas Hasanuddin dan RSUP. Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 12 Juni 2024 sampai 12 Juni 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

64	59256	68	P	LOW	WELL DIF	90	0	3	4	80	7	2	3	4	65	7	3	2	5	5	3	2	30	5	20	2	1	1	12	3	p120000	Keanu (Proximal)	Rectum	103
65	61516	44	P	LOW	WELL DIF	80	0	2	1	10	3	2	4	55	6	2	1	5	3	3	2	5	5	10	3	1	1	10	3	p120000	Keanu (Proximal)	Rectum	104	
66	61945	32	L	LOW	WELL DIF	80	0	0	0	0	0	0	0	10	0	3	4	55	7	3	3	30	6	70	3	1	1	20	3	p120000	Keanu (Proximal)	Rectum	105	
67	H20 805	8048	50	L	MODERATE	60	0	1	2	20	3	1	2	10	3	3	1	5	4	0	0	0	0	30	2	1	1	7	2	p120000	Kai (Distal)	Rectum	107	
68	H22 240	184800	52	L	MODERATE	50	0	3	4	60	7	3	4	55	7	3	4	10	4	0	0	0	10	4	1	1	9	2	p120000	Kai (Distal)	Rectum	108		
69	H22 1118	181724	51	L	WELL DIF	70	0	3	1	5	4	3	2	10	5	0	0	0	0	0	0	0	30	2	1	1	7	2	p120000	cek Unhas	Rectum	109		
70	H23 365	156860	55	L	MODERATE	50	0	3	1	10	4	3	2	10	5	2	2	5	4	0	0	0	0	10	1	1	8	2	p120000	Kai (Distal)	Rectum	110		
71	H23 269	102673	57	L	MODERATE	60	0	2	4	70	6	3	4	70	7	3	3	50	6	0	0	0	0	70	3	1	11	3	p120000	Kai (Distal)	Rectum	111		
72	P23 5678	282700	65	P	MODERATE	70	0	2	3	30	5	3	4	60	7	0	0	0	0	0	0	0	0	5	1	1	11	3	p120000	Kai (Distal)	Rectum	112		
73	P23 5634	102438	60	L	MODERATE	80	0	3	4	80	7	3	4	70	7	1	1	5	2	1	2	1	3	10	1	1	17	3	p120000	Kai (Distal)	Rectum	113		
74	P23 5630	109466	44	L	LOW	MODERATE	60	0	3	4	90	7	3	4	70	7	2	3	50	5	2	2	1	4	50	2	2	13	3	p120000	Kai (Distal)	Rectum	114	
75	P22 0667	959311	47	L	LOW	MUCINOUS	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	30	2	1	1	6	2	p120000	Kai (Distal)	Rectum	115	
76	P22 1665	962491	48	L	LOW	MODERATE	60	0	0	0	0	0	1	2	5	3	1	2	30	3	1	3	10	4	30	2	1	8	2	p120000	Kai (Distal)	Rectum	116	
77	P22 0413	87548	64	L	HIGH	POORLY	10	30	2	4	90	6	1	4	90	5	1	4	30	4	3	3	50	6	50	2	1	12	3	p120000	Kai (Distal)	Rectum	117	
78	P22 2702	996620	60	P	LOW	MODERATE	50	0	3	1	10	4	3	2	10	5	3	2	20	5	0	0	0	0	40	2	1	5	2	p120000	Kai (Distal)	Rectum	118	
79	P23 3735	996080	46	P	LOW	MODERATE	60	0	0	0	0	0	1	2	5	3	3	1	5	4	3	2	5	5	5	1	1	10	3	p120000	Kai (Distal)	Rectum	119	
80	P22 2728	979736	74	L	LOW	MODERATE	55	0	1	2	20	3	1	0	3	20	4	2	1	10	3	0	0	0	30	2	1	11	3	p120000	Kai (Distal)	Rectum	120	
81	P22 4789	1001329	41	P	LOW	MODERATE	60	0	0	0	0	0	0	0	0	0	0	3	3	30	6	2	2	10	3	10	1	6	2	p120000	Keanu (Proximal)	Rectum	121	
82	P22 0065	960044	52	L	LOW	MODERATE	55	0	0	0	0	0	2	4	30	5	3	3	10	6	2	4	60	6	30	2	1	9	2	p120000	Keanu (Proximal)	Rectum	122	
83	H23 909	208521	49	P	LOW	MODERATE	55	0	2	4	70	6	2	4	90	5	3	3	1	10	4	0	0	0	20	2	1	6	2	p120000	Keanu (Proximal)	Rectum	123	
84	P22 1680	979564	54	L	HIGH	POORLY	30	0	2	1	10	3	2	2	10	3	3	3	30	6	0	0	0	0	30	2	1	13	3	p120000	Keanu (Proximal)	Rectum	124	
85	H23 660	208731	51	L	LOW	MODERATE	60	0	0	0	0	0	1	2	10	3	3	3	30	6	1	2	10	3	35	2	1	7	2	p120000	Keanu (Proximal)	Rectum	125	
86	P22 0673	970672	46	L	LOW	MUCINOUS	20	80	1	1	10	2	2	3	30	5	3	1	5	4	2	2	10	4	20	2	1	10	3	p120000	Keanu (Proximal)	Rectum	126	
87	P22 2750	979401	55	L	LOW	MODERATE	60	0	2	3	30	5	1	3	50	4	2	3	30	5	1	4	60	5	45	2	1	6	2	p120000	Keanu (Proximal)	Rectum	127	
88	P22 4112	968863	60	L	LOW	MODERATE	55	0	3	4	40	4	1	2	10	3	3	1	10	4	0	0	0	0	35	2	1	9	2	p120000	Kai (Distal)	Rectum	128	
89	P22 1063	969224	45	L	LOW	MODERATE	60	0	3	4	70	7	2	3	50	5	3	1	5	4	0	0	0	0	10	1	1	6	2	p120000	Keanu (Proximal)	Rectum	129	
90	P22 0414	964717	58	L	LOW	MUCINOUS	45	55	2	4	60	6	3	3	50	6	3	1	10	4	0	0	0	0	10	1	1	15	3	p120000	Rectum	Rectum	130	
91	P22 02965	963720	70	L	LOW	MODERATE	60	0	2	3	35	5	1	3	50	4	3	3	50	6	0	0	0	0	75	3	1	3	1	p120000	Kai (Distal)	Rectum	131	
92	H23 04	208718	40	P	LOW	MODERATE	60	0	3	4	90	7	3	4	70	7	3	1	10	4	3	2	10	5	15	2	1	8	2	p120000	Kai (Distal)	Rectum	132	
93	H23 914	208812	49	L	LOW	MODERATE	60	0	0	3	75	7	3	4	90	7	3	1	10	4	0	0	0	0	20	2	2	10	3	p120000	Rectum	Rectum	133	
94	P22 5061	1001318	67	P	LOW	MUCINOUS	30	70	1	3	30	4	2	2	10	4	0	0	0	0	0	0	0	0	5	1	1	5	2	p120000	Keanu (Proximal)	Rectum	134	
95	P22 2066	980934	47	P	LOW	MODERATE	60	0	2	4	60	6	0	0	0	0	0	3	1	5	4	3	2	5	5	30	2	1	3	1	p120000	Kai (Distal)	Rectum	135
96	P22 1455	979055	65	P	LOW	MODERATE	55	0	0	0	0	0	0	0	0	0	0	3	1	10	4	1	2	5	3	30	2	1	15	3	p120000	Kai (Distal)	Rectum	136
97	P22 4246 /	993836	43	L	LOW	WELL DIF	90	0	3	3	50	6	3	3	50	6	3	3	30	6	3	2	10	5	20	2	1	6	2	p120000	Keanu (Proximal)	Rectum	137	
98	P22 1065	971316	46	P	LOW	WELL DIF	90	20	2	3	50	5	2	4	80	6	2	1	5	3	0	0	0	0	10	1	1	8	2	p120000	Kai (Distal)	Rectum	138	
99	P22 1900	973063	61	P	HIGH	POORLY	10	0	2	3	30	5	2	3	50	5	0	0	0	0	0	0	0	30	2	1	1	8	2	p120000	Kai (Distal)	Rectum	139	
100	P22 0028	958537	46	L	LOW	WELL DIF	50	0	2	3	30	5	1	2	10	3	2	3	30	5	0	0	0	0	10	1	1	10	3	p120000	Kai (Distal)	Rectum	140	
101	P22 0028 /	966642	39	P	HIGH	POORLY	10	0	1	3	30	4	1	3	30	4	3	1	10	4	0	0	0	0	10	1	1	8	2	p120000	Keanu (Proximal) dan	Kai (Distal)	141	
102	P21 1755	981292	40	L	LOW	WELL DIF	80	0	1	3	50	4	2	3	65	5	3	1	10	4	2	2	10	4	30	2	1	6	2	p120000	Rectum	Rectum	142	
103	P21 1532	979218	50	P	LOW	WELL DIF	75	0	2	3	30	5	2	4	70	6	2	1	10	3	2	2	10	4	35	2	1	9	2	p120000	Rectum	Rectum	143	
104	P21 1532	979218	39	L	LOW	MODERATE	50	0	2	3	50	5	3	4	70	7	3	3	2	15	5	2	2	10	4	30	2	1	12	3	p120000	Keanu (Proximal)	Rectum	144
105	P21 3289	959040	38	L	LOW	MODERATE	50	0	2	3	50	5	3	4	70	7	3	3	2	15	5	2	2	10	4	30	2	1	12	3	p120000	Keanu (Proximal)	Rectum	145
106	P21 3289	959040	31	P	LOW	WELL DIF	50	0	2	3	30	5	3	4	60	7	3	3	2	20	5	3	2	10	5	35	2	1	5	2	p120000	Kai (Distal)	Rectum	146
107	P21 3289	959040	53	L	LOW	WELL DIF	80	0	3	4	75	7	3	4	80	7	3	3	10	4	2	3	10	4	40	2	1	10	3	p120000	Rectum	Rectum	147	
108	P23 5989	1062283	78	L	LOW	WELL DIF	75	0	1	4	70	5	2	4	60	6	2	2	15	4	2	3	30	5	10	1	1	8	2	p120000	Keanu (Proximal)	Rectum	148	
109	P23 5992	467698	55	P	HIGH	POORLY	10	80	2	4	80	6	3	3	60	6	3	1	10	4	2	2	5	4	10	1	1	11	3	p120000	Rectum	Rectum	149	
110	P23 6531	1063115	55	P	HIGH	POORLY	10	80	2	4	80	6	3	3	60	6	3	1	10	4	2	2	5	4	10	1	1	11	3	p120000	Rectum	Rectum	150	
111	P23 6572	1085658	59	L	LOW	MODERATE	60	0	2	1	10	3	1	2	10	3	2	3	30	5	2	3	30	5	10	1	1	12	3	p120000	Rectum	Rectum	151	
112	P23 6572	1085658	57	P	LOW	MODERATE	55	0	3	4	80	7	3	4	80	7	2	2	15	4	1	2	5	3	20	2	1	4	1	p120000	Kai (Distal)	Rectum	152	
113	P23 6572	1085658	62	P	LOW	MODERATE	60	0	3	4	90	7	3	4	80	7	3	3	10	6	2	2	10	4	5	1	1	10	3	p120000	Keanu (Proximal)	Rectum	153	
114	P23 6572	1085658	40	P	LOW	WELL DIF	80	0	1	1	10	2	2	3	50	5	2	1	5	3	0	0	0	0	15	2	1	6	2	p120000	Kai (Distal)	Rectum	154	
115	P23 6572	1085658	62	L	HIGH	POORLY	20	0	1	4	70	5	2	3	50	5																		

123	P24.0988	692304	45	L		MALINOUS	30	70	2	4	75	6	1	4	80	5	3	3	50	6	0	0	0	0	0	5	1	2	1	11	3	p1360M0	Stage I/A	Kam (Proximal)	Microsc	123
124	P24.1175	1140521	48	L	LOW	WELL DFF	80	0	3	3	50	6	3	4	85	7	3	3	35	6	1	3	50	4	50	2	1	1	1	8	2	p1360M0	Stage I/A	Kri (Distal)		124
125	P24.1234	1135112	53	L	LOW	WELL DFF	65	10	3	4	70	7	3	4	75	7	3	3	30	6	1	2	10	3	10	1	1	1	1	6	2	p1360M0	Stage I/A	Rectum		125
126	P24.1242	1129147	52	P	HIGH	POORLY	35	0	2	4	70	6	2	4	60	6	2	1	10	3	0	0	0	0	30	2	1	1	1	9	2	p1360M0	Stage I/A	Kri (Distal)		126
127	P24.1357	1141198	46	L	LOW	WELL DFF	90	10	2	4	90	6	2	4	80	6	2	1	10	3	2	3	30	5	40	2	1	1	1	8	2	p1362aM0	Stage I/B	Kam (Proximal)		127
128	P24.1437	1062759	55	P	LOW	MODERATE	55	0	3	4	80	7	3	4	90	7	3	1	5	4	1	2	10	3	5	1	1	1	9	2	p1362aM0	Stage I/B	Kri (Distal)		128	
129	P24.1466	1125717	51	P	LOW	MODERATE	60	0	1	3	50	4	6	3	50	9	3	3	40	6	1	3	30	4	5	1	1	1	4	1	p1260M0	Stage I	Rectum		129	
130	P24.1469	1131997	67	P	LOW	MODERATE	65	0	0	0	0	0	3	4	70	7	1	3	30	4	1	2	1	3	30	2	1	1	3	1	p1260M0	Stage I	Rectum		130	
131	P24.1768	1148602	33	L	LOW	WELL DFF	90	0	1	4	70	5	1	3	50	4	3	3	15	6	2	3	30	5	32	2	1	1	1	12	3	p14M4Mc	Stage I/C	Kri (Distal)	MET A BUL	131
132	P24.1769	1140781	54	L	HIGH	POORLY	10	0	1	3	30	4	1	2	10	3	3	1	10	4	1	1	5	2	5	1	1	1	1	9	2	p1260M0	Stage I	Rectum		132